NEW YORK (GenomeWeb) – Akonni Biosystems announced today that it has received a $300,000 grant from the National Institutes of Health to finalize development of a rapid, point-of-care tuberculosis assay for use on the company's TruDx 3000 sample-to-answer diagnostic system.

The grant was awarded under the NIH's Commercialization Readiness Pilot program, which is designed to help small businesses transition projects previously funded by the agency into the commercialization stage.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.